Valuation: Personalis, Inc.

Market Cap 1.43B 1.25B 1.15B 1.06B 2.03B 136B 2.05B 13.72B 5.34B 66.78B 5.36B 5.24B 231B P/E 2026 *
-14x
P/E 2027 * -16x
Enterprise Value 1.27B 1.11B 1.02B 945M 1.8B 121B 1.82B 12.17B 4.74B 59.25B 4.75B 4.65B 205B EV / Sales 2026 *
16.1x
EV / Sales 2027 * 12.1x
Free-Float
73.33%
Yield 2026 *
-
Yield 2027 * -
1 day+5.29%
1 week+10.14%
Current month+7.01%
1 month+33.40%
3 months+117.93%
6 months+78.80%
Current year+80.15%
1 week 12.8
Extreme 12.8
14.83
1 month 9.08
Extreme 9.08
14.83
Current year 4.96
Extreme 4.955
14.83
1 year 3.84
Extreme 3.84
14.83
3 years 0.89
Extreme 0.8906
14.83
5 years 0.89
Extreme 0.8906
24.52
10 years 0.89
Extreme 0.8906
53.46
Manager TitleAgeSince
Chief Executive Officer 57 2023-03-01
Chief Executive Officer 65 2022-12-30
President 55 2026-03-12
Director TitleAgeSince
Director/Board Member 79 2019-04-30
Chairman 76 2022-05-16
Director/Board Member 72 2021-03-05
Date Insider Type Main position Quantity % Market Cap.
06-28Fiscal year

Chief Financial Officer

14,946 0.0143%
06-25Fiscal year

Chief Executive Officer

300,000 0.2865%
06-25Fiscal year

Chief Financial Officer

153,753 0.1468%
Change 5-day change 1-year change 3-year change Capi.($)
+5.29%+10.14%+92.48%+654.74% 1.43B
+1.08%+8.57%+3.61%+9.34% 49.92B
+0.40%+4.34%+401.69%+606.81% 40.23B
-0.52%+7.76%+25.41%-6.76% 34.55B
+3.97%+10.56%+26.06%+61.61% 33.09B
-4.19%+6.03%+3.76%+32.17% 27.51B
-2.40%+2.75% - - 17.05B
+1.34%+7.21%+75.77%+138.54% 15.92B
-0.95%-0.38%+12.92%+17.96% 13.86B
+1.69%+2.46%+93.44%+97.16% 13.52B
Average +0.63%+5.96%+81.68%+179.06% 24.71B
Weighted average by Cap. +0.36%+6.44%+91.14%+140.29%

Financials

2026 *2027 *
Net sales 78.74M 68.8M 63.37M 58.77M 112M 7.51B 113M 757M 295M 3.69B 296M 289M 12.76B 111M 97M 89.33M 82.85M 158M 10.59B 160M 1.07B 416M 5.2B 417M 408M 17.99B
Net income -107M -93.49M -86.11M -79.86M -152M -10.21B -154M -1.03B -401M -5.01B -402M -393M -17.34B -96.4M -84.23M -77.57M -71.94M -137M -9.19B -139M -927M -361M -4.51B -362M -354M -15.62B
Net Debt -161M -140M -129M -120M -228M -15.33B -231M -1.55B -602M -7.53B -604M -590M -26.05B -79.83M -69.75M -64.24M -59.58M -113M -7.61B -115M -768M -299M -3.74B -300M -293M -12.93B
Logo Personalis, Inc.
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Employees
260
Date Price Change Volume
26-07-06 US$14.34 +5.29% 4,555,979
26-07-02 US$13.62 -1.23% 3,788,616
26-07-01 US$13.79 +2.91% 3,966,602
26-06-30 US$13.40 -2.55% 4,099,363
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
14.34USD
Average target price
10.86USD
Spread / Average Target
-24.29%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PSNL Stock